Japan Eliquis Post-Marketing Survey: No Deaths, 8 Cases Of Major Bleeding
This article was originally published in PharmAsia News
Executive Summary
In the six-month period since its launch in Japan in February 2013, there have been no reports of deaths related to oral anticoagulant Eliquis (apixaban), according to a post-market surveillance report from Bristol-Myers Squibb and Pfizer.